| ₹ crore | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | 427 | 321 | +33.2% |
| EBITDA | 36.0 | 22.3 | +61.3% |
| EBITDA margin | 8.4% | 7.0% | +1.5 pts |
| Profit before tax | 28.2 | 18.5 | +52.4% |
| Net profit | 24.1 | 12.1 | +98.4% |
| EPS | ₹1.44 | ₹0.73 | +97.3% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 2,428 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 207 | 339 | 273 | 373 | 200 | ||
| 2,221 | — | — | — | — | ||
| 1,476 | 1,303 | 1,393 | 1,445 | 1,617 | ||
| — | −6.4% | −3.6% | −10.6% | — | ||
| 129 | 101 | 137 | 195 | 253 | ||
| 8.7% | 7.7% | 9.9% | 13.5% | 15.6% | ||
| 73.8 | 45.9 | 83.8 | 142 | 197 | ||
| 78.1 | 55.6 | 103 | 133 | 149 | ||
| 5.3% | 4.3% | 7.4% | 9.2% | 9.2% | ||
| ₹4.67 | ₹3.33 | ₹6.16 | ₹7.96 | ₹8.93 | ||
| — | −45.9% | −22.7% | −10.8% | — | ||
| — | 252 | 25.6 | 201 | 282 | ||
| — | −175 | −123 | −35.5 | −29.7 | ||
| 77.3 | 77.3 | −97.6 | 165 | 252 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 2,427.6 | |
| - Cash, Equiv & ST Investments | 199.9 | 372.6 | 273.4 | 338.8 | 206.5 | |
| Enterprise Value | — | — | — | — | 2,221.1 | |
| Revenue | 1,616.6 | 1,444.7 | 1,392.7 | 1,303.0 | 1,476.1 | |
| Growth %, YoY | — | -10.6 | -3.6 | -6.4 | — | |
| EBITDA | 252.7 | 195.0 | 137.4 | 100.8 | 129.1 | |
| Margin % | 15.63 | 13.50 | 9.87 | 7.73 | 8.75 | |
| EBIT | 197.1 | 142.3 | 83.8 | 45.9 | 73.8 | |
| Net Income | 149.2 | 133.0 | 102.9 | 55.6 | 78.1 | |
| Margin % | 9.23 | 9.21 | 7.39 | 4.27 | 5.29 | |
| EPS, Adj (current shares) | 8.93 | 7.96 | 6.16 | 3.33 | 4.67 | |
| Growth %, YoY | — | -10.8 | -22.7 | -45.9 | — | |
| Cash from Operations | 282.0 | 200.9 | 25.6 | 252.1 | — | |
| Capital Expenditures | -29.7 | -35.5 | -123.1 | -174.8 | — | |
| Free Cash Flow | 252.3 | 165.5 | -97.6 | 77.3 | 77.3 | |
Prices at the previous close · figures from the company's filings with NSE
NOCIL (NSE: NOCIL) had a market capitalisation of ₹2,428 crore at the previous close (₹145.35 a share), a PE ratio of 31.1 on the last four quarters' profit and a price-to-book ratio of 1.34. In FY26 its consolidated net profit was ₹55.6 crore on revenue of ₹1,303 crore; in Q2 FY27 (July–September 2026) it was ₹24.1 crore, up 98.4% year on year. It had no borrowings on 30 September 2026. Promoters held 33.76% of the shares on 30 September 2026.
NOCIL's PE ratio is 31.1 at the previous close (₹145.35 a share): a market capitalisation of ₹2,428 crore divided by consolidated net profit of ₹78.1 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹55.6 crore) it is 43.6.
NOCIL's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,806 crore on 30 September 2026, up 2.0% from ₹1,771 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹2,428 crore at the previous close.
NOCIL's book value per share was ₹108.15 on 30 September 2026: shareholders' equity of ₹1,806 crore divided by the 16.7 crore shares in issue, up 2.0% from ₹106.05 a year earlier. The share price at the previous close was ₹145.35.
NOCIL's price-to-book (PB) ratio is 1.34 at the previous close: a market capitalisation of ₹2,428 crore divided by shareholders' equity (book value) of ₹1,806 crore on 30 September 2026. That is a book value of ₹108.15 per share against a share price of ₹145.35.
In FY26, NOCIL's return on equity (ROE) was 3.2% and its return on capital employed (ROCE) was 2.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 5.9% and ROCE 4.5%.
NOCIL's dividend yield is 1.03% at the previous close: dividends of ₹1.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹145.35. They were ₹1.50 on 24 July 2026.
NOCIL's market capitalisation was ₹2,428 crore at the previous close: 16.7 crore shares at ₹145.35 each.
Yes. NOCIL had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹209 crore of cash, bank balances and current investments.
NOCIL's debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹1,806 crore. A year earlier, on 30 September 2025, it was 0.00.
NOCIL's basic earnings per share (EPS) were ₹3.33 in FY26, against ₹6.17 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹4.67.
In 2026, NOCIL has declared one dividend: ₹1.50 with record date 24 July 2026.
Promoters held 33.76% of NOCIL on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
On 30 September 2026, NOCIL's shares were held by promoters 33.76%, foreign portfolio investors (FII/FPI) 5.28%, domestic institutions (DII) 6.96% (including mutual funds at 6.03%) and retail and other non-institutional investors 53.99%. Over the year, FII holding was up 0.13 percentage points from 5.15% and DII holding was up 0.39 percentage points from 6.57%.
NOCIL's latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit ₹24.1 crore, up 98.4% from ₹12.1 crore in Q2 FY26; revenue from operations ₹427 crore, up 33.2% year on year.
In FY26, NOCIL earned net profit of ₹55.6 crore on revenue of ₹1,303 crore, against ₹751 crore on ₹4,661 crore for Himadri Speciality Chemical. NOCIL's operating margin was 3.5% (Himadri Speciality Chemical 19.2%) and its return on equity 3.2% (Himadri Speciality Chemical 17.8%).
In FY26, NOCIL generated ₹252 crore of cash from operations and spent ₹175 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹77.3 crore. In FY25 it was −₹97.6 crore.
In FY26 (April 2025–March 2026), NOCIL's consolidated net profit was ₹55.6 crore, down 45.9% from ₹103 crore in FY25, on revenue from operations of ₹1,303 crore (down 6.4%). Over three years, from FY23, net profit was down 62.7%.
NOCIL has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
On FY26 consolidated figures, against Himadri Speciality Chemical, Rossari Biotech and Navin Fluorine International: NOCIL's operating margin of 3.5% is the lowest of the four (Himadri Speciality Chemical 19.2%, Rossari Biotech 8.6%, Navin Fluorine International 28.1%; peer average 18.7%); its return on equity of 3.2% is the lowest of the four (Himadri Speciality Chemical 17.8%, Rossari Biotech 11.9%, Navin Fluorine International 20.1%; peer average 16.6%); its revenue growth over three years of −6.9% a year is the lowest of the four (Himadri Speciality Chemical 3.8% a year, Rossari Biotech 13.1% a year, Navin Fluorine International 16.8% a year; peer average 11.2% a year).
From NOCIL's own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.